OmniAb, Inc. (OABIW)

OmniAb, Inc. operates in the field of antibody engineering and therapeutic development—a specialized corner of biotechnology where the focus is on creating and optimizing human antibodies to treat disease. Antibodies are naturally occurring proteins that the body’s immune system produces to recognise and neutralise invading pathogens or abnormal cells. Over the past two decades, antibody-based drugs have become one of the most successful and fastest-growing classes of therapeutics, with some of the world’s best-selling medications now in the antibody family. OmniAb exists to design, engineer, and develop antibodies for other companies and to pursue its own antibody-based drug candidates.

The company’s strength lies in its technology platforms—proprietary methods for generating human antibodies with specific targeting properties and optimising them for therapeutic use. Like many platform biotechnology companies, OmniAb does not generate its own large sales force or perform extensive clinical trials alone. Instead, it typically partners with larger pharmaceutical or biotechnology companies that have more resources to conduct clinical trials, scale manufacturing, and bring drugs to market. Those partnerships generate revenue through milestone payments, royalties on future sales, and upfront licensing fees.

What antibodies can do

Antibodies work by binding to specific targets on the surface of diseased cells or circulating pathogens. A cancer-targeting antibody might bind to a protein expressed only on tumour cells, marking them for destruction by the immune system. An antibody against a viral protein might neutralise the virus directly. The beauty of antibodies as therapeutics is their specificity—they can be designed to hit a single target with minimal off-target effects, reducing the side-effect burden compared to small-molecule drugs that often affect multiple pathways.

The challenge is engineering antibodies that are specific enough, stable enough to persist in the bloodstream, and strong enough to generate a therapeutic effect. A naturally occurring antibody might work beautifully in a laboratory dish but be rejected or degraded in the human body. Antibody engineers work to humanise antibodies (swapping non-human portions with human equivalents), optimise their structure to enhance binding, and improve their half-life in the body. These optimisations require deep expertise in immunology, molecular biology, and protein chemistry.

The platform-driven model and its advantages

OmniAb’s approach of building proprietary platforms for antibody generation and optimisation is attractive to larger pharmaceutical companies because it reduces time and cost. Rather than starting from scratch to develop an antibody against a target of interest, a large pharma partner can use OmniAb’s platform to accelerate the process. The company might take a fee for the platform access or a license, plus milestone payments if the antibody advances in development and royalties if the resulting drug sells successfully.

This model has a built-in limit on scale. A platform company can serve multiple partners and multiple projects simultaneously, but it does not, on its own, capture the enormous value that accrues when a drug reaches the market. If OmniAb engineers an antibody that becomes a multi-billion-dollar medication, the company receives milestone payments and royalties—meaningful but far smaller than the value captured by the company that conducted the clinical trials, manufactured the drug at scale, and brought it to market. Pharmaceutical giants like Roche, Merck, and Amgen have absorbed platform companies and integrated them, capturing far more of the value chain.

Business model and cash flow

OmniAb generates revenue through collaborative partnerships. A larger company pays an upfront fee to access OmniAb’s platform and capabilities, then pays additional milestones as projects hit predetermined targets (successful generation of a lead antibody, regulatory approval, first commercial sale). Once a drug reaches the market, the platform company receives a royalty on sales, typically ranging from 2% to 10% depending on the negotiated deal.

The advantage of this model is recurring revenue and a share of upside without the capital intensity of manufacturing scale or the regulatory burden of conducting trials. The disadvantage is that the company’s growth is dependent on the success of its partners’ development and commercialisation efforts—factors outside OmniAb’s direct control. If a partner’s trial fails or is terminated, the milestone stream stops. If a partner’s antibody-based drug never reaches the market, the royalty never materialises.

From antibodies to market

The timeline from an antibody engineering project to a marketed drug is measured in years. OmniAb might spend six months to two years optimising a specific antibody for a partner’s target. The partner then conducts preclinical toxicology and manufacturing work (one to three years), followed by Phase 1, Phase 2, and Phase 3 clinical trials (another five to ten years), and finally regulatory review and approval. Throughout that process, OmniAb receives milestone payments if the partnership agreement specifies them. If the drug eventually reaches patients and is adopted at scale, royalties begin flowing.

The company’s ability to sustain itself depends on maintaining a portfolio of partnerships—ideally, a mix of early-stage programs (smaller near-term revenue but potentially larger future royalties) and late-stage programs closer to commercialisation (more reliable near-term milestone payments). A company with no mature partnerships in the clinic faces considerable risk and likely requires raising capital to fund operations until its platform generates enough partnership royalties to break even.

The competitive landscape and scale effects

Antibody engineering is a crowded field. Academic institutions, large pharmaceutical companies, and specialist biotechs all have antibody discovery and optimisation capabilities. Smaller, focussed companies like OmniAb must differentiate through superior technology—a platform that generates better antibodies faster, or with superior properties—or through relationships and track record. The first successful antibody developed through a partnership becomes a reference point; investors and potential partners point to it as proof of concept.

Small to mid-sized antibody companies often face acquisition as they grow. Once an antibody engineered using their platform shows genuine promise and begins generating significant milestone payments, a large pharmaceutical company may find it more efficient to acquire the platform company and integrate it rather than continue as a licensor. For OmniAb’s shareholders, such an acquisition would represent a major inflection point—potentially a multibillion-dollar valuation if the acquired antibody is successful. For the company itself, acquisition typically means integration into a larger R&D organisation and a shift from independent platform company to an internal centre of excellence.

Investors researching OmniAb should focus on the company’s partnership portfolio—how many programs, at what stages, with which partners—and on the track record of those partnerships to date. Any program that has reached clinical trials or commercial use is a success case worth scrutinising. The company’s cash position and burn rate matter because they determine runway before the partnership royalties need to sustain operations. And the quality and reputation of the scientific leadership shapes both the likelihood that the platform generates competitive antibodies and the company’s ability to attract top talent in a competitive field.